Sexual Dysfunction in Women Treated for Type 1 Diabetes and the Impact of Coexisting Thyroid Disease

Abstract

Introduction More sexual problems are reported among people treated for diabetes; however, this situation is less explored in women than in men. Aim To analyze the presence and causal links of female sexual dysfunction (FSD) among Czech women treated for type 1 diabetes. Methods 40 women completed a national version of the Female Sexual Function Index (FSFI), Female Sexual Distress Scale-revised (FSDS-R), and Beck’s Depression Inventory–II (BDI-II). A metabolic and endocrine analysis was done using blood samples. Data were statistically analyzed using SPSS v.24 and the R environment. Main Outcome Measures Patient details (personal information, diabetes-related data, and sex history), sexual performance (the FSFI and FSDS-R scores), and level of depression (the BDI-II score) were measured. Results FSD was present in 58% of the participants (based on the FSFI score), and 38% women declared significant sexual distress (according to their FSDS-R score). Even though only 4 women fulfilled the criteria for depression, we observed a strong association between BDI-II and FSFI (for total FSFI score P = .012, ρ = −0.394) resp. FSDS-R scores ( P < .001, ρ = 0.552). Although we were not able to establish a clear direct connection between FSD and metabolic control, BDI-II scores were closely correlated with glycosylated hemoglobin ( P = .009, ρ = 0.407). The duration of diabetes (based on FSDS-R: P = .046) but neither age nor the presence of chronic diabetic microvascular complications was associated with a higher FSD occurrence. We also observed an association between FSD and the presence of autoimmune hypothyroidism, even when successfully treated (FSDS-R: P = .009; FSFI: P = .067). Conclusion FSD is more common in women with type 1 diabetes than in healthy women, and coexisting thyroid autoimmune disease seems to exacerbate FSD. Women suffering from type 1 diabetes, and particularly those with additional endocrinopathies, should be actively screened for FSD. Stechova K, Mastikova L, Urbaniec K, et al. Sexual Dysfunction in Women Treated for Type 1 Diabetes and the Impact of Coexisting Thyroid Disease. Sex Med 2019;7:217–226.

Risk factors for sexual dysfunction in Romanian women with type 1 diabetes mellitus and chronic autoimmune thyroiditis: a comparative cross-sectional study

“…According to recent studies, the prevalence of FSD is higher in patients with DM than in the general population. In women with T1DM, the prevalence of FSD varies between 18 and 71%, and the odds ratio is 2.27 in patients with FSD [ 36 ]. A study performed by Ezlin et al reported that sexual dysfunction was more frequent in women with T1DM than in healthy women (27 vs. 15%), with a predominance of decreased lubrication [ 37 ].…”

Mobile health applications for improving the sexual health outcomes among adults with chronic diseases: A systematic review

“…This demonstrates that m-health interventions addressing sexual problems for patients with chronic diseases have not been considered sufficiently over the last 10 years. Although various chronic diseases such as diabetes, hypertension, inflammatory bowel disease and so on can affect sexual functioning, [38][39][40] reviewed studies mostly considered breast or prostate cancer for female or male patients, respectively, indicating that more research is needed for the evaluation of m-health interventions aiming at sexual health improvement in patients with other chronic disease and considering other types of cancer as well.…”

Relationship between adherence to anti-diabetic medication and depression among patients with diabetes mellitus in three selected Chinese hospitals

“…The cutoff for depression is 20 [13]. The scoring of BDI II is as follows: 1 -10 = normal; 11 -20 = mild mood disturbances; 20 -25 = borderline clinical depression; 25 -30 = moderate depression; 31-40 = severe depression, and > 40 = extreme depression [14].…”